California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
The US Court of Appeals for the Federal Circuit last week reversed a Patent Trial and Appeal Board decision, which found that claims in an OSI Pharmaceuticals patent for cancer treatment were obvious.
Goldfinch Bio, a US company focused on developing treatments for kidney disease, has agreed to license a cannabinoid receptor 1 antibody from Japanese pharmaceutical manufacturer Takeda.
The US Patent and Trademark Office (USPTO) has granted a new CRISPR-Cas9 patent to the University of California (UC), the University of Vienna and Emmanuelle Charpentier, marking the fifth consecutive week that the USPTO has approved a new patent in their CRISPR portfolio.
Canadian pharmaceutical company Bausch Health is suing Sandoz for patent infringement over its notice of intent to release a generic version of Xifaxan, Bausch’s irritable bowel syndrome drug.
Evolve BioSystems and the University of California have jointly sued Abbott Laboratories for patent infringement over a soon-to-be-launched probiotic product.
Taiwan-based Personal Genomics Taiwan has taken gene-sequencing rival Pacific Biosciences to court in the US, over alleged patent infringement.
Bayer and two Boston hospitals have joined forces in a chronic lung disease research product, with the trio championing the ‘joint lab’ model as a blueprint for pharmaceutical research.
Greensfelder, Hemker & Gale has appointed Jared Manse to its St Louis office as an associate in the firm’s IP Practice Group.
The US Court of Appeals for the Federal Circuit has ruled that delays resulting from challenges to patent examiners’ final decisions will be attributed to the applicant when calculating patent term adjustment.